QMed, Inc. Release: Heart Failure Demonstration Project Terminated

2006-01-11
EATONTOWN, N.J., Jan. 11 /PRNewswire-FirstCall/ -- QMed, Inc. today announced that PacifiCare Health System has notified the Centers for Medicare and Medicaid Services (CMS), and the Company that PacifiCare will terminate the HeartPartners demonstration project effective February 28, 2006. The project was originally scheduled to end on December 31, 2006 and the early termination will have an approximate $3.5 million revenue impact on QMed in 2006. Michael W. Cox, president and CEO, said, "Termination of the demonstration project has no impact on our Company's strategic plan to expand our special needs offerings to other markets, which is currently proceeding." About QMed, Inc. QMed provides evidence-based clinical information management systems around the country to its health plan customers. The system incorporates Disease Management services to patients and decision support to physicians. The Company's QMedCare subsidiary specializes in serving high-risk populations of Medicare beneficiaries. Health e Monitoring is QMed's subsidiary offering weight, obesity and health promotion programs. The Company has been selected and operates in two Medicare Demonstrations to test the feasibility of reimbursing its care coordinated DM services in the vast Medicare fee-for-service program. More information on QMed, Inc. can be obtained at , by calling (732) 544-5544 or by emailing investor@qmedinc.com. Except for historical information contained herein, matters discussed in this news release are forward-looking statements that involve risks and uncertainties. They include but are not limited to those relating to the timely implementation of programs, the impact of competitive product introductions, acceptance and pricing, and those risks detailed in the Company's filings with the Securities and Exchange Commission (SEC). Actual results may differ materially from any forward-looking statements due to these risks and uncertainties. QMed, Inc. CONTACT: Robert Mosby, QMed, Inc., +1-732-544-5544, Ext. 1107 Web site:
适应症
靶点
-
药物
-
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI,赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台,以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。